Emodepside: the anthelmintic’s mode of action and toxicity
Nematode parasitic infections continue to be a major health problem for humans and animals. Drug resistance to currently available treatments only worsen the problem. Drug discovery is expensive and time-consuming, making drug repurposing an enticing option. Emodepside, a broad-spectrum anthelmintic...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Parasitology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpara.2024.1508167/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850108282017939456 |
|---|---|
| author | Charity N. Njeshi Alan P. Robertson Richard J. Martin |
| author_facet | Charity N. Njeshi Alan P. Robertson Richard J. Martin |
| author_sort | Charity N. Njeshi |
| collection | DOAJ |
| description | Nematode parasitic infections continue to be a major health problem for humans and animals. Drug resistance to currently available treatments only worsen the problem. Drug discovery is expensive and time-consuming, making drug repurposing an enticing option. Emodepside, a broad-spectrum anthelmintic, has shown efficacy in the treatment of nematode parasitic infections in cats and dogs. It is now being considered and trialed for the treatment of onchocerciasis, trichuriasis (whipworm), and hookworm infections in humans. Its unique mechanism of action distinguishes it from traditional anthelmintics, positioning it as a promising candidate for combating resistance to other current drugs. Here, we provide a brief review of the available information on emodepside’s pharmacokinetics, safety, and tolerability. We highlight the potential benefits and risks associated with its use, examining key toxicity effects. By exploring the literature, we aim to provide insights into the risks associated with emodepside that may impact its application in veterinary and human medicine. Although emodepside demonstrates a favorable safety profile, continued monitoring of its toxicity is crucial, particularly in vulnerable populations. This mini-review serves as a concise resource for researchers and clinicians interested in anthelmintic therapy. |
| format | Article |
| id | doaj-art-f584897a4d7941b6a8e91a9ebf69acd4 |
| institution | OA Journals |
| issn | 2813-2424 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Parasitology |
| spelling | doaj-art-f584897a4d7941b6a8e91a9ebf69acd42025-08-20T02:38:25ZengFrontiers Media S.A.Frontiers in Parasitology2813-24242024-12-01310.3389/fpara.2024.15081671508167Emodepside: the anthelmintic’s mode of action and toxicityCharity N. NjeshiAlan P. RobertsonRichard J. MartinNematode parasitic infections continue to be a major health problem for humans and animals. Drug resistance to currently available treatments only worsen the problem. Drug discovery is expensive and time-consuming, making drug repurposing an enticing option. Emodepside, a broad-spectrum anthelmintic, has shown efficacy in the treatment of nematode parasitic infections in cats and dogs. It is now being considered and trialed for the treatment of onchocerciasis, trichuriasis (whipworm), and hookworm infections in humans. Its unique mechanism of action distinguishes it from traditional anthelmintics, positioning it as a promising candidate for combating resistance to other current drugs. Here, we provide a brief review of the available information on emodepside’s pharmacokinetics, safety, and tolerability. We highlight the potential benefits and risks associated with its use, examining key toxicity effects. By exploring the literature, we aim to provide insights into the risks associated with emodepside that may impact its application in veterinary and human medicine. Although emodepside demonstrates a favorable safety profile, continued monitoring of its toxicity is crucial, particularly in vulnerable populations. This mini-review serves as a concise resource for researchers and clinicians interested in anthelmintic therapy.https://www.frontiersin.org/articles/10.3389/fpara.2024.1508167/fullemodepsideSLO-1Ktoxicityanthelminticpharmacokineticsriver blindness |
| spellingShingle | Charity N. Njeshi Alan P. Robertson Richard J. Martin Emodepside: the anthelmintic’s mode of action and toxicity Frontiers in Parasitology emodepside SLO-1K toxicity anthelmintic pharmacokinetics river blindness |
| title | Emodepside: the anthelmintic’s mode of action and toxicity |
| title_full | Emodepside: the anthelmintic’s mode of action and toxicity |
| title_fullStr | Emodepside: the anthelmintic’s mode of action and toxicity |
| title_full_unstemmed | Emodepside: the anthelmintic’s mode of action and toxicity |
| title_short | Emodepside: the anthelmintic’s mode of action and toxicity |
| title_sort | emodepside the anthelmintic s mode of action and toxicity |
| topic | emodepside SLO-1K toxicity anthelmintic pharmacokinetics river blindness |
| url | https://www.frontiersin.org/articles/10.3389/fpara.2024.1508167/full |
| work_keys_str_mv | AT charitynnjeshi emodepsidetheanthelminticsmodeofactionandtoxicity AT alanprobertson emodepsidetheanthelminticsmodeofactionandtoxicity AT richardjmartin emodepsidetheanthelminticsmodeofactionandtoxicity |